Akari Therapeutics Plc (AKTX) Free cash flow 2016–2023
Akari Therapeutics Plc (AKTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$16.4MFY2023 · since FY2016: -$24.7M → -$16.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$16.4M | +24.1% |
| FY2022 | -$21.6M | — |
| FY2019 | -$12.9M | +43.3% |
| FY2018 | -$22.8M | +28.0% |
| FY2017 | -$31.6M | -28.2% |
| FY2016 | -$24.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AKTX financial trends
AKTX RevenueAKTX Net incomeAKTX Net marginAKTX Gross profitAKTX Gross marginAKTX Operating incomeAKTX Operating marginAKTX Operating cash flowAKTX Capital expendituresAKTX Return on equityAKTX Stock buybacksAKTX Dividends paidAKTX Total assetsAKTX Total liabilitiesAKTX Shareholders’ equityAKTX overview →